Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 110351-94-5 | MDL No. : | |
Formula : | C13H13NO5 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | IGKWOGMVAOYVSJ-ZDUSSCGKSA-N |
M.W : | 263.25 | Pubchem ID : | 10220900 |
Synonyms : |
|
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P271-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
93% | With trifluoroacetic acid; at 20℃; for 6h; | The intermediate M14 (1.0 g, 3.26 mmol) was dissolved in trifluoroacetic acid (30 ml),The reaction was stirred at room temperature for 6 hours, and was concentrated by rotary evaporation to obtain a dark brown oily liquid.Purification by silica gel column chromatography (dichloromethane: ethyl acetate = 4: 1) gave 0.88 g of a pale yellow solid with a yield of 93%. |
87% | With trifluoroacetic acid; In water; at 20℃; for 3h;Inert atmosphere; | (S)-4?-ethyl-4?-hydroxy-7?,8?-dihydrospiro[[1,3]dioxolane-2,6?-pyrano[3,4-f]indolizine]-3?,10?(1?H,4 ?H)-dione(270 mg, 0.88 mmol) and a mixture of trifluoroaceticacid (2 mL) and water (0.5 mL) were stirred under N2 at roomtemperature for 3 h. After concentration under vacuum, the resulting residue was purified by column chromatographyto give the title compound (202 mg, 87 %). 1H NMR (CDCl3): delta 7.22 (1H, s), 5.68 (1H, d, J = 17.2 Hz), 5.24 (1H, d, J =17.2 Hz), 4.36-4.32 (2H, m), 3.65 (1H, s), 2.99-2.95 (2H, m), 1.84-1.78 (2H, m), 0.98 (3H, t, J = 7.6 Hz). |
87% | With trifluoroacetic acid; In water; at 20℃; for 3h;Inert atmosphere; | (S)-4?-ethyl-4?-hydroxy-7?,8?-dihydrospiro[[1,3]dioxolane-2,6?-pyrano[3,4-f]indolizine]-3?,10?(1?H,4?H)-dione (270 mg, 0.88 mmol) and a mixture of trifluoroaceticacid (2 mL) and water (0.5 mL) were stirred under N2 at room temperature for 3 h. After concentration under vacuum, the resulting residue was purified by column chromatography to give the title compound (202 mg, 87%), 1H NMR (CDCl3): delta7.22 (1H, s), 5.68 (1H, d, J=17.2 Hz), 5.24 (1H, d, J=17.2 Hz), 4.36-4.32 (2H, m), 3.65 (1H, s), 2.99-2.95 (2H, m), 1.84-1.78 (2H, m), 0.98 (3H, t, J=7.6 Hz). |
With trifluoroacetic acid; In ethyl acetate; | REFERENTIAL EXAMPLE 1 (4S)-4-Ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione To 90 ml of 90% trifluoroacetic acid, 3.5 g of (4S)-4-ethyl-6,6-(ethylenedioxy)-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,10(4H)-dione were added at room temperature over 5 minutes, followed by stirring at the same temperature for 30 minutes. After completion of the reaction, the solvent was removed under reduced pressure, followed by the thorough removal of the solvent by a vacuum pump. To the residue so obtained was added 20 ml of ethyl acetate. The crystals precipitated were collected by filtration, whereby 2.4 g of the title compound were obtained. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
75% | With iodine; magnesium; In N,N-dimethyl-formamide; at 90℃; for 0.583333h;Microwave irradiation; | A 10 mL reaction flask was placed on a magnetic stirrer, and substituted o-aminopiperonal (ketone) II-1 (123.8 mg, 0.75 mmol), tricycloketone lactone III (131.5 mg, 0.5 mmol) and iodine (12.7) were added. Mg, 0.05mmol), slowly add N, N-dimethylformamide (1.5mL) and stir for 5 minutes, put into the microwave reactor, set the power 100W, heating temperature 90 C, heatingOpen the exhaust fan for 30 minutes. After the reaction was completed, the mixture was cooled to room temperature, quenched with ice water, extracted with dichloromethane and brine, and the organic phase was collected, dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (eluent is dichloromethane/ethyl acetate, v/v = 4:1),The pale yellow target product (147.5 mg, yield 75%, purity ? 98%) was obtained. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With hydrogenchloride; acetic acid; In ethanol; water; at 110 - 115℃; for 24h; | Step III: Preparation of Irinotecan base ( VII, Ri = C2H5)Dissolve Step- II product(11.5) in ethyl alcohol (115ml) ,added con. HCl (25.4ml) , glacial acetic acid (115ml), 14CPT (10.62g) and heat the mixture to 1 10°- 1 15°C for a period of 24 hrs. Evaporate the reaction mixture to dryness, add water (345ml) and stir for 10-15 mih and filter the aqueous solution through celite bed. The filtered aqueous solution is extracted with chloroform (4x85ml). Separated organic and aqueous layer. Aqueous layer is evaporated to dryness under vacuum. Add ethyl alcohol (80ml) to dissolve the residue, add activated charcoal (1.15g) and heat to 70°C with string for an hour. Filter the hot solution and cool to room temperature with stirring and then to 00C for an overnight. The precipitated pale yellow <n="9"/>solid is filtered to obtain is step- III product(10.4g) having HPLC purity of not less than98.00percent. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With hydrogenchloride; acetic acid; In ethanol; water; at 110 - 115℃; for 24h;Product distribution / selectivity; | Step III: Preparation of Irinotecan base ( VII, Rj = C2Hs)Dissolve Step- II product(11.5) in ethyl alcohol (115ml) ,added con. HCl (25.4ml) , glacial acetic acid (115ml), 14CPT (10.62g) and heat the mixture to 1 10°- 1 15°C for a period of 24 <n="10"/>hrs Evaporate the reaction mixture to dryness, add water (345ml) and stir for 10-15 min and filter the aqueous solution through celite bed. The filtered aqueous solution is extracted with chloroform (4x85ml). Separated organic and aqueous layer. Aqueous layer is evaporated to dryness under vacuum. Add ethyl alcohol (80ml) to dissolve the residue, add activated charcoal (1.15g) and heat to 7O0C with string for an hour. Filter the hot solution and cool to room temperature with stirring and then to 0°C for an overnight. The precipitated pale yellow solid is filtered to obtain is step- III product(10.0 g) having HPLC purity of not less than 98.00percent. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With hydrogenchloride; acetic acid; In ethanol; water; at 110 - 115℃; for 24h;Product distribution / selectivity; | Step III: Preparation of Irinotecan base ( VII, R] = C2H5) Dissolve Step- II product(l l.O) in ethyl alcohol (110ml) ,added con. HCl (24.2ml) , glacial acetic acid (110ml), 14CPT (10.Og) and heat the mixture to 110°- 115°C for a period of 24 hrs. Evaporate the reaction mixture to dryness, add water (345ml) and stir for 10-15 min and filter the aqueous solution through celite bed. The filtered aqueous solution is extracted with chloroform (4x85ml). Separated organic and aqueous layer. Aqueous layer is evaporated to dryness under vacuum. Add ethyl alcohol (80ml) to dissolve the residue, add activated charcoal (1.15g) and heat to 700C with string for an hour. Filter the hot solution and cool to room temperature with stirring and then to 00C for an overnight. The precipitated pale yellow solid is filtered to obtain is step- III product(lpsi.psig) having HPLC purity of not less than 98.00percent. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In acetic acid; at 115℃; for 22h; | A solution of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate as prepared in Example 1 (0.359 g, 1.0 mmol) and 14CPT (the compound of formula (I) above) (0.39 g, 1.5 mmol) in 10 ml acetic acid was heated to 115° C. for 22 hours. The resulting mixture was distilled under vacuum to yield a black semisolid residue. The residue was dissolved in a 95:5 (v/v) methylene chloride/methanol mixture and chromatographed on 20 g silica-60 (230-400 mesh), eluting with 95:5 (v/v) methylene chloride/methanol (400 ml) and then 92.5:7.5 (v/v) methylene chloride/methanol (600 ml). The resulting product fractions were combined and evaporated to provide a residue, which was then redissolved in 20 ml methylene chloride and washed with saturated aqueous sodium bicarbonate solution (2.x.10 ml). The resulting organic phase was dried over sodium sulfate and evaporated. Ethanol was added and the resulting solution concentrated to a volume of 8 ml before being allowed to crystallize overnight. The solids were filtered and dried to yield 0.243 g of irinotecan (CPT-11 free base) as a pale yellow solid. The irinotecan produced as above (0.216 g) was dissolved in 2 ml water and 0.43 ml 1M HCl and heated to 60° C. to form a yellow solution. This solution was filtered hot over powdered activated carbon (Darco.(TM). m G-60) (0.5 g). The filtrate was cooled and seeded with 5 mg irinotecan hydrochloride crystals and allowed to crystallize overnight. The solids were filtered, washed with water (2.x.1 ml), and suction dried under air to yield 0.123 g of irinotecan hydrochloride trihydrate as pale yellow crystals having a melting point of 259.8° C. | |
In acetic acid; at 115℃; for 22h; | A solution of 4-amino-3-propionylphenyl-1, 4';-bipiperidine-1';-carboxylate as prepared in Example 1 (0.359 g, 1.0 mmol) and 14CPT (the compound of formula (I) above) (0. 39 g, 1.5 mmol) in 10 rnl acetic acid was heated to 115C for 22 hours. The resulting mixture was distilled under vacuum to yield a black semisolid residue. The residue was dissolved in a 95: 5 (v/v) methylene chloride/methanol mixture and chromatographed on 20 g silica-60 (230-400 mesh), eluting with 95: 5 (v/v) methylene chloride/methanol (400 ml) and then 92.5 : 7.5 (v/v) methylene chloride/methanol (600 ml). The resulting product fractions were combined and evaporated to provide a residue, which was then redissolved in 20 ml methylene chloride and washed with saturated aqueous sodium bicarbonate solution (2 X 10 ml). The resulting organic phase was dried over sodium sulfate and evaporated. Ethanol was added and the resulting solution concentrated to a volume of 8 rnl before being allowed to crystallize overnight. The solids were filtered and dried to yield 0.243 g of irinotecan (CPT-11 free base) as a pale yellow solid. The irinotecan produced as above (0.216 g) was dissolved in 2 ml water and 0.43 ml 1M HC1 and heated to 60 C to form a yellow solution. This solution was filtered hot over powdered activated carbon (Darco G-60) (0.5 g). The filtrate was cooled and seeded with 5 mg irinotecan hydrochloride crystals and allowed to crystallize overnight. The solids were filtered, washed with water (2 x 1 ml), and suction dried under air to yield 0.123 g of irinotecan hydrochloride trihydrate as pale yellow crystals having a melting point of 259. 8C. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In acetic acid; | EXAMPLE 6 Preparation of (S)-9-ethyl-2,3-dihydro-4,9-dihydroxy-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-10,13(9H,15H)-dione: (in formula IA, Z=--CH2 --, R1 =4-OH, R2 =H, and R3 =Et) In 120 ml of acetic acid 1.44 g of 8-amino-3,4-dihydro-5-hydroxy-1(2H)-naphthalenone hydrochloride (in formula II, Z=--CH2 --, m=0, n=2, R1 =5-OH, R2 =H) and 1.94 g of (S)-7,8-dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (in formula III, R3 =Et) were dissolved and the mixture was stirred at 100 C. for 11 hours. Following this, the same procedure was repeated as in Example 1 to obtain the title compound. mp: 221-226 C. (dec.) [alpha]D3 =-23.0 C. (C =0.235, in DMSO) NMR (DMSO-d6) delta: 0.94 (3H, t, J=7 Hz, CH3), 1.70-2.40 (4H, m, C2 --H & CH2 CH3), 2.80-3.30 (4H, m, C2 --H & C3 --H), 5.20 (2H, s, CH2 --N), 5.46 (2H, s, CH2 --O), 7.29 (1H, s, C8 --H), 7.50 {1H, d, J=8.9 Hz, C5 --H), 7.86 (1H, d, J=8.9 Hz, C6 --H) IR numaxKBr cm-1: 3428, 1740, 1658, 1592 Elemental analysis for C23 H20 N2 O5.1/2H2 O: Calculated: C 66.82; H 5.12; N 6.78; Found: C 67.10; H 5.04; N 6.55. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
The oily substance was crystallized from a mixed solvent of ethanol and petroleum ether to obtain 170 mg of the title compound as colorless needle-like crystals. Specific rotatory power [alpha]D =+121.42 (C=0.532, chloroform). | ||
EXAMPLE 8 (S)-7,8-Dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (I*c) Dissolved in 80% trifluoroacetic acid was 120 mg of the compound (I*b) of this invention obtained in the procedure (6) of Example 7. The resultant mixture was continuously stirred at room temperature for 1.5 hours under a nitrogen gas stream. The reaction mixture was concentrated and dichloromethane was added to the residue. After washing the thus-prepared mixture first with 5% NaHCO3 and then with water, the mixture was dried over anhydrous sodium sulfate and then concentrated. The residue was crystallized from a mixed solvent of ethanol and petroleum ether to obtain 81 mg of the title compound as colorless needle-like crystals. Melting point: 172-174 C. Specific rotatory power [alpha]D +117.6 (C=0.56, chloroform). NMR (CDCl3) delta: 0.98(3H, t, J=7 Hz, --CH2 CH3), 1.82(2H, q, J=7 Hz, --CH2 CH3), 2.96(2H, t, J=7 Hz, C7 --H), 3.75(1H, s, --OH), 4.35(2H, t, J=7 Hz, C8 --H) 5.24,5.63(2H, ABq, J=17 Hz, C1 --H), 7.23(1H, s, C5 --H), IR numaxKBr cm-1: 1740, 1660, 1610. Elemental analysis: Calculated for C13 H13 NO5.1/4H2 O: C, 58.32; H, 5.08; N, 5.23. Found: C, 58.15; H, 4.89; N, 5.27. | ||
The oily substance was crystallized from a mixed solvent of ethanol and petroleum ether to obtain 170 mg of the title compound as colorless needle-like crystals. Specific rotatory power [alpha]D= +121.42 (C=0.532, chloroform). |
Example 8 (S)-7,8-Dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]-indolizine-3,6,10(4H)-trione (I*c): Dissolved in 80% trifluoroacetic acid was 120 mg of the compound (I*b) of this invention obtained in the procedure (6) of Example 7. The resultant mixture was continuously stirred at room temperature for 1.5 hours under a nitrogen gas stream. The reaction mixture was concentrated and dichloromethane was added to the residue. After washing the thus-prepared mixture first with 5% NaHCO3 and then with water, the mixture was dried over anhydrous sodium sulfate and then concentrated. The residue was crystallized from a mixed solvent of ethanol and petroleum ether to obtain 81 mg of the title compound as colorless needle-like crystals. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
(2) (S)-4-Ethyl-7,8-dihydro-4-hydroxy-1H-pyrano-[3,4-f]indolizine-3,6,10(4H)-trione (I*c): Dissolved in 15 ml of dimethoxyethane was 815 mg of the compound (VI) obtained in the above procedure (1), followed by an addition of 5 ml of 2N H2SO4. The thus-prepared solution was heated with stirring for 20 hours under a nitrogen gas stream. After completion of the reaction, 150 ml of dichloromethane was added and the resultant mixture was washed with water. The organic layer was then dried over anhydrous sodium sulfate and the solvent was distilled off. The residue was recrystallized from a mixed solvent of ethanol and petroleum ether to obtain 315 mg of the title compound as colorless needle-like crystals. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
40% | With zinc(II) chloride; In ethanol; at 70℃; for 5h;Molecular sieve; Inert atmosphere; | The ketone of formula III (990 mg, 3.74 mmol), ZnCl2 (3.8 g, 28.08 mmol) and molecular sieves were added to a solution of 2-amino-6-(2-methoxyethoxymethoxymethyl)-benzaldehyde in EtOH and the mixture was heated at 70C under an atmosphere of nitrogen for 5 h. Ethanol was removed in vacuo and the residue was purified by flash chromatography with CH2Cl2/CH3OH 97:3 to give 9-(2-methoxyethoxymethoxymethyl)camptothecin as a white solid. Yield 830 mg (40%), 1H NMR (CDCl3) delta: 1.06 (t, 3H, J= 7.44 Hz, -CH3); 1.79-1.99 (m, 2H, -CH2); 3.43 (s, 3H, -OMe); 3.59 (t, 2H, -CH2O-, J = 4.84 Hz); 3.75 (t, 2H, -CH2O-, J = 4.84 Hz); 4.85 (s, 2H, -OCH2Ph-); 5.10 (s, 2H, -OCH2O-); 5.28, 5.74 (AB, -CH2); 5.31 (2H, s, -CH2); 7.25 (s, 1H, 1Ar); 7.67(d, 1H, 1Ar, J = 8.19 Hz); 7.76 (dd, 1H, 1Ar, J = 8.19, 8.19 Hz); 8.19 (d, 1H, 1Ar, J = 8.19 Hz); 8.75 (s, 1H, H-7). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
96% | With toluene-4-sulfonic acid; acetic acid; In toluene; at 100℃; for 24h; | A-Ring (7) (20 mg) and CDE-ring (4) (16 mg) were dissolved in a mixture of acetic acid and toluene (1 mL; 1:1 v/v). Toluensulfonic acid (1 mg) was added and the reaction mixture was stirred at 100 C. for 24 hours. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was then washed 2-times with hexane (2×10 mL) and dried under vacuum. The crude material was purified by silica gel column with a yield of 27 mg (96%). The spectral data were confirmed to be identical to commercially BNP1350 (Karenitecin; Cositecan). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
98% | With toluene-4-sulfonic acid; acetic acid; In toluene; at 100℃; for 20h; | To a solution of 1-(2-amino-phenyl)-3-trimethylsilanyl-propan-1-one (3) (34 mg) and CDE ring moiety (4) (24 mg) in acetic acid (0.5 mL) and toluene (1 mL) was added p-toluenesulfonic acid (1 mg). The reaction solution was stirred for 20 hours at 100 C. After cooling to room temperature, the reaction solution was concentrated under reduced pressure and the residue was washed with hexane (10 mL), water (10 mL), and a mixture of acetone (5 mL) and hexane (5 mL). The yellow solid was evaporated to dryness in vacuo to yield 39 mg (98% Yield) of BNP1350 (Karenitecin; Cositecan; 7-(2'-trimethylsilyl)ethyl camptothecin; IUPAC Nomenclature: (4S)-4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-1H-pyrano[3':4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione). 1H NMR (300 MHz, CDCl3) delta 8.24 (d, 1H, J=8.4 Hz), 8.05 (d, 1H, J=7.5 Hz), 7.82 (t, 1H, J=7.2 Hz), 7.71-7.66 (m, 2H), 5.77 (d, 1H, J=16.2 Hz), 5.33 (d, 1H, J=16.2 Hz), 5.26 (s, 2H), 3.73 (s, 1H), 3.15-3.09 (m, 2H), 1.96-1.86 (m, 2H), 1.03 (t, 3H, J=7.5 Hz), 0.91-0.98 (m, 2H), 0.19 (s, 9H). 13C NMR (300 MHz, CDCl3) delta 174.15, 157.91, 152.17, 150.41, 149.75, 147.34, 147.24, 130.98, 130.20, 127.84, 126.83, 126.28, 123.49, 118.67, 98.21, 73.01, 66.59, 49.48, 31.86, 24.32, 18.00, 8.04, -1.65. MS: 449 (M+1); Chiral Purity: 100% ee. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
58.8% | With toluene-4-sulfonic acid; acetic acid; In toluene; at 100℃; for 24h; | To a solution of 1-(2-aminophenyl)-3-(trimethylsilyl)propan-1-one HCl salt (14) (1165.5 mg) and (4) (700 mg) in acetic acid (29 mL) and toluene (29 mL), was added p-toluenesulfonic acid (58.5 mg) to give a light yellow solution. The resulting solution was stirred at 100 C. for 24 hours. After cooled to room temperature, the solution was concentrated to dryness. The residue was slurried in isopropanol (12 mL) and stirred at room temperature for 30 minutes. The solid product was collected by vacuum filtration. The wet cake was washed 3-times with isopropanol (3*1 mL) to produce an off-white solid, which was dried in vacuo to give 820 mg (58.8% yield) of the desired BNP1350 (Karenitecin; Cositecan) product in 99.2% purity. |
[ 64439-81-2 ]
4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Similarity: 0.75
[ 239463-85-5 ]
(R)-3-(5-(2-Aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate (2R,3R)-2,3-dihydroxysuccinate
Similarity: 0.69
[ 115662-09-4 ]
8-Hydroxy-1,1,7,7-tetramethyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carbaldehyde
Similarity: 0.64
[ 64439-81-2 ]
4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Similarity: 0.75
[ 103030-10-0 ]
Methyl 2,3-dioxoindoline-7-carboxylate
Similarity: 0.71
[ 147770-06-7 ]
(S)-Ethyl 2-ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoate
Similarity: 0.71
[ 337909-10-1 ]
Ethyl 1-formyl-4-oxo-4H-quinolizine-3-carboxylate
Similarity: 0.69
[ 153072-43-6 ]
Methyl 2,3-dioxoindoline-4-carboxylate
Similarity: 0.69
[ 64439-81-2 ]
4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Similarity: 0.75
[ 103030-10-0 ]
Methyl 2,3-dioxoindoline-7-carboxylate
Similarity: 0.71
[ 147770-06-7 ]
(S)-Ethyl 2-ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoate
Similarity: 0.71
[ 89331-94-2 ]
6'-(Dibutylamino)-3'-methyl-2'-(phenylamino)-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
Similarity: 0.69
[ 70516-41-5 ]
6'-(Ethyl(isopentyl)amino)-3'-methyl-2'-(phenylamino)-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
Similarity: 0.69
[ 103030-10-0 ]
Methyl 2,3-dioxoindoline-7-carboxylate
Similarity: 0.71
[ 153072-43-6 ]
Methyl 2,3-dioxoindoline-4-carboxylate
Similarity: 0.69
[ 81937-39-5 ]
Diethyl 2-(1-(4-acetamidophenyl)-1-oxopropan-2-yl)malonate
Similarity: 0.68
[ 302776-68-7 ]
Hexyl 2-(4-(diethylamino)-2-hydroxybenzoyl)benzoate
Similarity: 0.67
[ 190595-65-4 ]
(3R,4S)-4-(4-(Benzyloxy)phenyl)-1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)azetidin-2-one
Similarity: 0.66
[ 64439-81-2 ]
4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Similarity: 0.75
[ 89331-94-2 ]
6'-(Dibutylamino)-3'-methyl-2'-(phenylamino)-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
Similarity: 0.69
[ 70516-41-5 ]
6'-(Ethyl(isopentyl)amino)-3'-methyl-2'-(phenylamino)-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
Similarity: 0.69
[ 337909-10-1 ]
Ethyl 1-formyl-4-oxo-4H-quinolizine-3-carboxylate
Similarity: 0.69
[ 29512-49-0 ]
6'-(Diethylamino)-3'-methyl-2'-(phenylamino)-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
Similarity: 0.69
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :